Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Crit Rev Food Sci Nutr ; 57(12): 2611-2622, 2017 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-27222914

RESUMEN

Conjugated alpha linolenic acid (CLNA) isomers are promising lipids owing to their similarities with conjugated linoleic acid (CLA) but exerting their bioactivity at lower doses; some isomers also belong to omega 3 family. This review aims to summarize the state of the art about the utilization of CLNA as a functional ingredient. Indeed, in vitro and in vivo studies reported that CLNA exerted anticancer, anti-inflammatory, anti-obese, and antioxidant activities. However, CLNA has not been tested in humans. These compounds are naturally present in meat and milk fat from ruminants but the highest concentrations are found in vegetable oils. Their incorporation in foodstuffs is one of the most effective strategies to elaborate CLNA-enriched products together with the microbiological production. Lactobacilli, propionibacteria, and bifidobacteria strains have been assayed to produce CLNA isomers but at the current moment there are not high CLNA concentration products elaborated using these strains. Furthermore, it is known that CLNA isomers are highly prone to oxidation when compared with linoleic acid and CLA, but the possible effects of elaboration and storage on high CLNA productsare unknown.The utilization of CLNA as a functional compound still remains a challenge and requires more research to address all of its technological and bioactivity aspects.


Asunto(s)
Ácidos Linoleicos Conjugados/uso terapéutico , Ácido alfa-Linolénico/uso terapéutico , Antiinflamatorios/química , Antiinflamatorios/uso terapéutico , Fármacos Antiobesidad/química , Fármacos Antiobesidad/uso terapéutico , Anticarcinógenos/química , Anticarcinógenos/uso terapéutico , Bifidobacterium , Alimentos , Humanos , Factores Inmunológicos/química , Factores Inmunológicos/uso terapéutico , Isomerismo , Ácidos Linoleicos Conjugados/química , Ácido alfa-Linolénico/química
2.
Microbiol Mol Biol Rev ; 82(4)2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30158254

RESUMEN

Conjugated linoleic acids (CLAs) and conjugated linolenic acids (CLNAs) have gained significant attention due to their anticarcinogenic and lipid/energy metabolism-modulatory effects. However, their concentration in foodstuffs is insufficient for any therapeutic application to be implemented. From a biotechnological standpoint, microbial production of these conjugated fatty acids (CFAs) has been explored as an alternative, and strains of the genera Propionibacterium, Lactobacillus, and Bifidobacterium have shown promising producing capacities. Current screening research works are generally based on direct analytical determination of production capacity (e.g., trial and error), representing an important bottleneck in these studies. This review aims to summarize the available information regarding identified genes and proteins involved in CLA/CLNA production by these groups of bacteria and, consequently, the possible enzymatic reactions behind such metabolic processes. Linoleate isomerase (LAI) was the first enzyme to be described to be involved in the microbiological transformation of linoleic acids (LAs) and linolenic acids (LNAs) into CFA isomers. Thus, the availability of lai gene sequences has allowed the development of genetic screening tools. Nevertheless, several studies have reported that LAIs have significant homology with myosin-cross-reactive antigen (MCRA) proteins, which are involved in the synthesis of hydroxy fatty acids, as shown by hydratase activity. Furthermore, it has been suggested that CLA and/or CLNA production results from a stress response performed by the activation of more than one gene in a multiple-step reaction. Studies on CFA biochemical pathways are essential to understand and characterize the metabolic mechanism behind this process, unraveling all the gene products that may be involved. As some of these bacteria have shown modulation of lipid metabolism in vivo, further research to be focused on this topic may help us to understand the role of the gut microbiota in human health.


Asunto(s)
Bifidobacterium/enzimología , Lactobacillus/enzimología , Ácidos Linoleicos Conjugados/biosíntesis , Ácidos Linolénicos/biosíntesis , Propionibacterium/enzimología , Animales , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Bifidobacterium/genética , Humanos , Isomerasas/genética , Isomerasas/metabolismo , Lactobacillus/genética , Metabolismo de los Lípidos/fisiología , Propionibacterium/genética , Ratas , Ratas Wistar
3.
MethodsX ; 2: 475-84, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-27408824

RESUMEN

Despite their important role in tissues, fluids and foods, the analysis of non-esterified fatty acids (NEFA) as methyl esters (NEFAME) is performed using expensive, cumbersome and time-consuming procedures that needs of isolation, fractionation and derivatization steps. However, Yi et al. [1] proposed a promising in situ, single-step procedure to analyze esterified fatty acids (EFA) and NEFA from a same sample on the basis that acylglycerols and free fatty acids can be derivatized using specific reactions. However, according to the data presented in this research work, some modifications need to be performed to increase the reliability of the method:•Increment of the transesterification performance by adding hexane to the reaction mixture, decreasing the time for the derivatization of acylglycerols from 10 min to 3-4 min and stopping the reaction with sulfuric acid.•Avoid cross-contamination of the NEFAME extract by adding 500 µL of water after collection of EFA methyl esters (EFAME).•Samples are spiked with three internal standards: a triacylglycerol (to calculate the concentration of EFA), a free fatty acid (to calculate NEFA) and a FAME (to control isolation of FAME and cross-contamination).

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA